Wu S Y, Reggio R, Florsheim W H
Endocrinology. 1985 Mar;116(3):901-8. doi: 10.1210/endo-116-3-901.
To further characterize the effect of TSH administration on thyroid iodothyronine monodeiodinating activity, we have evaluated the in vitro conversion of T4 to T3 (outer ring deiodination) and T3 to 3,3'-diiodothyronine (T2; inner ring deiodination) by mouse thyroid, liver, and kidney homogenates, comparing tissues from TSH-treated mice (0.1-200 mU bovine TSH, ip, for 1-3 days) with tissues from saline-treated controls. The in vitro conversion activity was studied in the presence of 1-20 mM dithiothreitol; most of the studies were carried out at 4 mM. Studies were carried out at optimal pH 6.5 for outer ring and 7.8 for inner ring deiodination. The iodothyronine monodeiodinase in mouse thyroid is similar to the ones in liver and kidney. It is heat labile (inactivated at 56 C for 5 min), inhibited by propylthiouracil (0.2 mM) and ipodate (0.2 mM), and unaffected by methimazole (up to 20 mM), ascorbate (up to 0.1 M) or KI (up to 20 mM). The mean +/- SE baseline rates of T4 to T3 and T3 to T2 conversion were 100 +/- 6.3 and 56.5 +/- 2.9 pmol/mg thyroid protein X 30 min at 37 C, respectively. A significant increase in each conversion activity was found after TSH treatment (0.2 U, ip, daily for 3 days); T4 to T3 conversion rose to 282 +/- 15.4, and T3 to T2 increased to 153 +/- 7.4 pmol/mg thyroid protein (P less than 0.001). A 12.8% increase in thyroid weight was found in the TSH-treated group (P less than 0.03 compared with saline control group). Similar but less marked increased in monodeiodinating activities were seen in the liver. A minimal but significant increase in inner ring monodeiodination with no significant increase in T4 to T3 converting activity was found in kidney, which, in the mouse, has markedly less outer ring deiodinase than liver or thyroid. The iodothyronine monodeiodinating activities did not increase until 12 h in thyroid and 48 h in liver after the first dose of TSH. Significant increases in T4 to T3 and T3 to T2 conversion were seen with doses of TSH as low as 0.1 mU (ip, daily for 3 days), and there was a linear dose-response thereafter. The decay of the increased iodothyronine monodeiodinating activities after a single dose of TSH (0.2 U) appeared to be linear, with a decay t 1/2 of 1.3 days for T4 to T3 conversion and about 1.0 day for T3 to T2 conversion.(ABSTRACT TRUNCATED AT 400 WORDS)
为了进一步阐明促甲状腺激素(TSH)对甲状腺碘甲状腺原氨酸单脱碘酶活性的影响,我们评估了小鼠甲状腺、肝脏和肾脏匀浆中T4向T3(外环脱碘)以及T3向3,3'-二碘甲状腺原氨酸(T2;内环脱碘)的体外转化情况,将接受TSH处理的小鼠(腹腔注射0.1 - 200 mU牛TSH,持续1 - 3天)的组织与接受生理盐水处理的对照小鼠的组织进行比较。体外转化活性是在1 - 20 mM二硫苏糖醇存在的情况下进行研究的;大多数研究在4 mM下进行。研究在外环脱碘的最佳pH 6.5和内环脱碘的7.8条件下开展。小鼠甲状腺中的碘甲状腺原氨酸单脱碘酶与肝脏和肾脏中的类似。它对热不稳定(56℃ 5分钟即失活),受丙硫氧嘧啶(0.2 mM)和碘番酸(0.2 mM)抑制,不受甲巯咪唑(高达20 mM)、抗坏血酸盐(高达0.1 M)或碘化钾(高达20 mM)影响。在37℃时,T4向T3以及T3向T2转化的平均±标准误基线速率分别为100±6.3和56.5±2.9 pmol/mg甲状腺蛋白×30分钟。TSH处理后(腹腔注射0.2 U,每日一次,共3天),每种转化活性均显著增加;T4向T3的转化升至282±15.4,T3向T2的转化增至153±7.4 pmol/mg甲状腺蛋白(P<0.001)。TSH处理组的甲状腺重量增加了12.8%(与生理盐水对照组相比,P<0.03)。肝脏中也观察到单脱碘酶活性有类似但不太明显的增加。在肾脏中,内环单脱碘有最小但显著的增加,而T4向T3的转化活性无显著增加,在小鼠中,肾脏的外环脱碘酶明显少于肝脏或甲状腺。首次注射TSH后,甲状腺中的碘甲状腺原氨酸单脱碘酶活性直到12小时才增加,肝脏中则是48小时。TSH剂量低至0.1 mU(腹腔注射,每日一次,共3天)时,T4向T3以及T3向T2的转化就显著增加,此后存在线性剂量反应关系。单次注射TSH(0.2 U)后,碘甲状腺原氨酸单脱碘酶活性增加后的衰减似乎呈线性,T4向T3转化的衰减半衰期为1.3天,T3向T2转化约为1.0天。(摘要截断于400字)